Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
0.010 | GeneticVariation | BEFREE | Another patient with the S310F mutation had an apocrine carcinoma with seven lymph nodes positive for metastasis, classified as HER2 3+ by the HercepTest, but which was FISH-negative, as well as ER-negative and PgR-negative. | 26642960 | 2016 |
||||
|
0.010 | GeneticVariation | BEFREE | Sequencing of the progressing metastasis allowed the identification of the ERBB2 L869R mutation previously associated with resistance to lapatinib in vitro.These results support further clinical investigation aiming to demonstrate that ERBB2-mutational driven therapy can improve patient care irrespective of histology. | 29941010 | 2018 |
||||
|
0.010 | GeneticVariation | BEFREE | Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. | 18237245 | 2008 |
||||
|
0.010 | GeneticVariation | BEFREE | In another case, EML4-ALK fusion detected in the primary tumor was associated with ALK G1202R secondary resistance mutation in the post-treatment metastasis. | 30946933 | 2019 |
||||
|
0.010 | GeneticVariation | BEFREE | Therefore, we initially studied the effect of rs61552325 on androgen-independent prostate cancer cell metastasis. | 28422721 | 2017 |
||||
|
0.010 | GeneticVariation | BEFREE | No significant associations were found in relation to susceptibility (CCR2-V64I: OR 1.32; 95 % CI 0.57-3.06; CCR5-∆32: OR 1.04; 95 % CI 0.60-1.81), clinical outcome (tumor size, lymph nodes commitment and/or distant metastasis, TNM staging and nuclear grade) or therapeutic response (recurrence and survival). | 25716470 | 2016 |
||||
|
0.010 | GeneticVariation | BEFREE | <i>XRCC1</i> rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer. | 30568466 | 2018 |